It says if semaglutide is not delivering the expected result, the usual clinical answer is to move to a dual GLP-1 and GIP agent, which lets a provider assess tolerance on a single mechanism and adjust based on response
The next update tracking GLP-1 usage and obesity trends is expected in mid-2027
Once activated, these dendritic cells release interleukin-23, a cytokine that drives the differentiation and expansion of TH17 cells
Liposomal delivery allows for efficient digestion and nutrient absorption
In the world of high-stakes biological research, were often focused on the big picturethe groundbreaking peptides, the complex experimental designs, the ambitious objectives
Dose adjustments to either medication may be needed to optimize your mental and physical health balance